Cargando…
Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer*
Eighty patients with advanced metastatic renal cancer have been treated with hormones, chiefly medroxyprogesterone acetate (Provera). This progestational compound is remarkably free from side-effects and can be given in high dosage for long periods without serious complications. Ninety per cent of c...
Autor principal: | Bloom, H. J. G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1971
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2008447/ https://www.ncbi.nlm.nih.gov/pubmed/5115827 |
Ejemplares similares
-
Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
por: Lam, Clarissa, et al.
Publicado: (2016) -
Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera
por: Halpern, Vera, et al.
Publicado: (2021) -
Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial()()
por: Nanda, Kavita, et al.
Publicado: (2016) -
Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate
por: Yuasa-Shibasaki, Erina, et al.
Publicado: (2017) -
Changes in Hematologic Parameters during Treatment with Medroxyprogesterone Acetate for Breast Cancer
por: Yamamoto, Hitoshi, et al.
Publicado: (1991)